Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Xilio Therapeutics, Inc.NASDAQ: XLO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 68.8% from a year ago

Cash & equivalents stood at $150.33M at the end of Q1 FY2026, up 68.8% from a year earlier and up 9.3% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.

Context

  • Cash & equivalents amounted to 92.0% of total assets at the end of Q1 FY2026, up 6.1 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +68.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$150.33M+9.3% QoQ
Last fiscal yearDec 2025
$137.53M+148.7% YoY
Year agoMar 2025
$89.07M+68.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+68.8%——
1 year+148.7%——
3-year CAGR+4.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
137.53M USD
Year-over-year change
+148.7%
4-year CAGR
-8.7%

Cash & Equivalents vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's Mar 2026 cash & equivalents of $150.33M is the 2nd highest of the 4 companies compared; the peer median is $36.47M.
  • Its year-over-year change of +68.8% is the 2nd highest of 4, against a peer median of -39.1%.
  • Cash & equivalents amounts to 92.0% of total assets for XLO, versus a peer median of 90.8%.
XLO Competitors Peer median
Cash & Equivalents for XLO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OKUROnKure Therapeutics, Inc.Mar 2026$192.11M +98.7%+72.3%96.7%
XLOXilio Therapeutics, Inc.Mar 2026$150.33M +68.8%+4.5%92.0%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$36.47M -39.1%-23.9%90.8%
PDSBPDS Biotechnology CorporationMar 2026$21.66M -45.8%-28.7%87.8%
Peer median (excluding XLO) $36.47M-39.1%-23.9%90.8%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents198.05M120.39M44.7M55.29M137.53M
Short-term Investments00000
Net Receivables00005M
Inventory00000
Other Current Assets4.46M4.11M3.42M4.94M2.5M
Total Current Assets202.52M124.5M48.13M60.23M145.03M
Property, Plant & Equipment (Net)13.9M12.84M11.2M9.06M7.85M
Goodwill00000
Intangible Assets00000
Long-term Investments1.55M1.56M01.78M1.81M
Tax Assets3.54M0000
Other Non-current Assets90K267K1.6M00
Total Non-current Assets19.08M14.67M12.8M10.84M9.66M
Total Assets221.6M139.17M60.93M71.08M154.69M
Account Payables3.14M3.13M1.05M2.57M3.17M
Short-term Debt883K6.67M3.32M00
Tax Payables00000
Deferred Revenue00013.52M40.02M
Other Current Liabilities3.61M82K6.9M4.21M5.73M
Total Current Liabilities12.78M21.12M15.96M27.26M56.27M
Long-term Debt9.63M3.17M000
Deferred Tax Liabilities3.54M0000
Deferred Revenue (Non-current)00019.26M0
Other Non-current Liabilities045K0057.53M
Total Non-current Liabilities23.39M12.4M8.14M26.22M63.14M
Total Liabilities36.17M33.52M24.1M53.48M119.41M
Common Stock3K3K3K5K36.89M
Retained Earnings(160.89M)(249.11M)(325.51M)(383.75M)(418.79M)
Accumulated OCI00000
Other Stockholders Equity0000417.17M
Minority Interest00000
Total Equity185.43M105.65M36.83M17.6M35.27M
Total Debt20.74M19.94M11.46M8.14M6.95M
Net Debt(177.32M)(100.45M)(33.25M)(47.15M)(130.58M)

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.